San Francisco US 12 - 15 July 2025

Endocrine Society (ENDO 2025)

Presentation schedule and materials
Saturday, 12 July 2025
12:15  - 13:45
PDT
POSTER
Association Between Engagement With The WeGoTogether Digital Self-support App And Weight Loss In A Real-world Setting
Joshua Toliver1; Victoria Divino1; Carmen Ng1; Julia Wang1
MATERIALS AVAILABLE
sat_694_wegotogether_poster_julia_wang
Poster
12:15  - 13:45
PDT
SAT-220
POSTER
Real-world evidence of treatment patterns and costs of Turner syndrome and Noonan syndrome in the United States
Andrew Dauber, MD, MMSc1; M Jennifer Abuzzahab, MD2; Jing Voon Chen, PhD3; Nicky Kelepouris, MD3; Moshe Fridman, PhD4; Morgan Shy, MD4; Scott Bunner, MPH5; Alicia Romano, MD6; Vaneeta Bamba, MD7
MATERIALS AVAILABLE
kelepouris_sat-220_pngc_poster_endo
Poster
pngc_ps_endo_poster-tour-deck_recording
Video
12:15  - 13:45
PDT
SAT-057
POSTER
Patient and caregiver preferences for once-weekly injection devices for the treatment of growth hormone deficiency
Jing Voon Chen, PhD1; Bradley S. Miller, MD, PhD2; Nicky Kelepouris, MD1; Ben Kantor, BASc3; Lisa Marin, BA3; Chris Platt, BS3; Kevin C.J. Yuen, MD, FRCP, FACE, FEAA4
MATERIALS AVAILABLE
miller_sat-057_la-gha_preferences_poster_endo
Poster
la-gha_ps_endo_poster-tour-deck-with-recording
Video
12:15  - 13:45
PDT
SAT-212
POSTER
Long-term safety and efficacy of somapacitan in short children born small for gestational age: 4-year results from a global phase 2 trial
Anders Juul1,2; Michael Højby3; Masanobu Kawai4; Agnès Linglart5; Jun Mori6, Nehama Zuckerman-Levin7; Philippe Backeljauw8; on behalf of the REAL 5 study group
MATERIALS AVAILABLE
long-term-safety-and-efficacy
Poster
12:15  - 13:45
PDT
SAT-185
POSTER
First real-world evidence of somapacitan therapy initiation in children with GHD from GloBE-Reg
Abdulmoein Al-Agha1; Aristides Maniatis2; Dirk Schnabel3,4; Alberto Pietropoli5; Kirstine Belling6; Faisal Ahmed7,8; Primoz Kotnik9,10.
MATERIALS AVAILABLE
first-real-world-evidence
Poster
12:15  - 13:45
PDT
SAT-187
POSTER
Efficacy and safety of somapacitan in non-GHD adolescents with short stature: 26-week results from the REAL9 phase 3 study
Aristides Maniatis1; Michael Højby2; Muhammad Yazid Jalaludin3; Alexander A. L. Jorge4; Jun Mori5; Kamil Soltysik2; Renata Stawerska6,7; Agnéès Linglart8.
MATERIALS AVAILABLE
efficacy-and-safety
Poster
14:45  - 15:00
PDT
OR03-06
ORAL PRESENTATION
Acutely regulated genes in children born small for gestational age following daily and weekly growth hormone are predictive of first-year growth response
Terence Garner1; Philip Murray1,2; Michael Højby3; Ryan Anthony Ard3; Peter Clayton1,2; and Adam Stevens1
MATERIALS AVAILABLE
garner-endo-25-real-oral-presentation-final-copy
Slide
Monday, 14 July 2025
12:00  - 13:30
PDT
POSTER
Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes
Carmen Ng1; Victoria Divino1; Julia Wang1; Joshua Toliver1; Marcio Buss1
MATERIALS AVAILABLE
mon_716_shape_poster_julia_wang
Poster
Keywords
Rare Endocrine Disorder
Diabetes
Obesity
ENDO